Long Noncoding RNA IGF2AS is Acting as an Epigenetic Tumor Suppressor in Human Prostate Cancer

Area of Science:

• Molecular Biology
• Cancer Research
• Epigenetics

Background:

• Prostate cancer (PCa) remains a leading cause of cancer-related deaths globally.
• Understanding the regulatory mechanisms of PCa progression is crucial for developing effective treatments.
• Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.

Purpose of the Study:

• To investigate the expression profile of the lncRNA insulin growth factor 2 antisense (IGF2AS) in human prostate cancer.
• To elucidate the functional mechanism of IGF2AS in PCa cell proliferation and invasion.
• To explore the relationship between IGF2AS and insulin growth factor 2 (IGF2) in PCa.

Main Methods:

• Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was used to measure IGF2AS expression in PCa cell lines and tumors.
• Lentivirus-mediated overexpression of IGF2AS was performed in PCa cells to assess its effects in vitro and in vivo xenograft models.
• IGF2 expression levels were analyzed following IGF2AS manipulation, and rescue experiments were conducted by upregulating IGF2.

Main Results:

• IGF2AS expression was found to be significantly downregulated in both PCa cell lines and human PCa tissues.
• Overexpression of IGF2AS suppressed PCa cell proliferation and invasion in vitro and inhibited tumor growth in vivo.
• IGF2AS overexpression led to decreased IGF2 levels, and restoring IGF2 levels reversed the tumor-suppressive effects of IGF2AS.

Conclusions:

• The lncRNA IGF2AS functions as an epigenetic tumor suppressor in human prostate cancer.
• IGF2AS exerts its tumor-suppressive role likely through inverse regulation of IGF2.
• The IGF2AS/IGF2 axis represents a promising therapeutic target for future PCa treatments.